Diagnosis and management of critical illness polyneuropathy and critical illness myopathy

被引：18

作者：

Bird S.J. ^{[1
]}

机构：

[1] Department of Neurology, University of Pennsylvania, Philadelphia, PA 19104

来源：

Current Treatment Options in Neurology | 2007年 / 9卷 / 2期

关键词：

Critical Illness; Intensive Insulin Therapy; Critical Illness Polyneuropathy; Critical Illness Myopathy; Compound Muscle Action Potential Amplitude;

D O I：

10.1007/s11940-007-0034-1

中图分类号：

学科分类号：

摘要：

Newly acquired neuromuscular weakness commonly develops in the setting of critical illness. This weakness delays recovery and often causes prolonged ventilator dependence. An axonal sensory-motor polyneuropathy, critical illness polyneuropathy (CIP), is seen in up to a third of critically ill patients with the systemic inflammatory response syndrome (usually due to sepsis). As frequently, or more so, an acute myopathy, critical illness myopathy (CIM), develops in a similar setting, often in association with the use of corticosteroids and/or nondepolarizing neuromuscular-blocking agents. This paper reviews the clinical features, diagnostic approach, and treatment of CIP and CIM. There are no specific pharmacologic treatments for CIP or CIM, but recognizing the presence of one of these disorders often improves management. Prevention of CIP and CIM is feasible in part by avoiding risk factors and by aggressive medical management of critically ill patients. Intensive insulin therapy in intensive care unit patients appears to reduce the likelihood of developing CIP and/or CIM. Future treatments of sepsis may further reduce the incidence of these neuromuscular consequences of critical illness. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：85 / 92

页数：7

共 45 条

[11]

Bird S.J., Rich M.M., Critical illness myopathy and polyneuropathy, Curr Neurol Neurosci Rep, 2, pp. 527-533, (2002)

[12]

Bolton C.F., Sepsis and the systemic inflammatory response syndrome: Neuromuscular manifestations, Crit Care Med, 24, pp. 1408-1416, (1996)

[13]

Op de Coul A.A.W., Lambregts P.C., Koeman J., Et al., Neuromuscular complications in patients given Pavulon (pancuronium bromide) during artificial ventilation, Clin Neurol Neurosurg, 87, pp. 17-22, (1985)

[14]

Hirano M., Ott B.R., Raps E.C., Et al., Acute quadriplegic myopathy: A complication of treatment with steroids, nondepolarizing blocking agents, or both, Neurology, 42, pp. 2082-2087, (1992)

[15]

Hanson P., Dive A., Brucher J.M., Et al., Acute corticosteroid myopathy in intensive care patients, Muscle Nerve, 20, pp. 1371-1380, (1997)

[16]

Lacomis D., Giuliani M.J., Van Cott A., Kramer D.J., Acute myopathy of intensive care: Clinical, electromyographic, and pathological aspects, Ann Neurol, 40, pp. 645-654, (1996)

[17]

Rich M.M., Teener J.W., Raps E.C., Et al., Muscle is electrically inexcitable in acute quadriplegic myopathy, Neurology, 46, pp. 731-736, (1996)

[18]

Rich M.M., Bird S.J., Raps E.C., Et al., Direct muscle stimulation in acute quadriplegic myopathy, Muscle Nerve, 20, pp. 665-673, (1997)

[19]

Trojaborg W., Weimer L.H., Hays A.P., Electrophysiologic studies in critical illness associated weakness: Myopathy or neuropathy - A reappraisal, Clin Neurophysiol, 112, pp. 1586-1593, (2001)

[20]

Bednarik J., Lukas Z., Vondracek P., Critical illness polyneuromyopathy: The electrophysiological components of a complex entity, Intensive Care Med, 29, pp. 1505-1514, (2003)

← 1 2 3 4 5 →